Women survive breast cancer but fall victim to heart failure: The shadows and lights of targeted therapy

Journal of Cardiovascular Medicine

Volumn 11, Issue 12, 2010, Pages 861-868

  Maurea, Nicola ^a   Coppola, Carmela ^a   Ragone, Gianluca ^b   Frasci, Giuseppe ^a   Bonelli, Annamaria ^a   Romano, Carmela ^b   Iaffaioli, Rosario Vincenzo ^b  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b Department of Colorectal Oncology ^*  (Italy)

Author keywords

breast cancer; cardiac insufficiency; cardiotoxicity; target therapy

Indexed keywords

ANASTROZOLE; ANTHRACYCLINE; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; APOLIPOPROTEIN E; BEVACIZUMAB; BISOPROLOL; CAPTOPRIL; CARBOPLATIN; CARVEDILOL; CHOLESTEROL; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; ENALAPRIL; EXEMESTANE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LETROZOLE; LISINOPRIL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PACLITAXEL; RAMIPRIL; SUNITINIB; TAMOXIFEN; TRASTUZUMAB; TRIACYLGLYCEROL;

BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CARDIOMYOPATHY; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; DISEASE SEVERITY; DRUG EFFECT; FEMALE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HUMAN; HYPERTENSION; LIPOPROTEIN BLOOD LEVEL; MULTIPLE CYCLE TREATMENT; REVIEW; SIDE EFFECT; SYSTOLIC DYSFUNCTION; THROMBOEMBOLISM; TRIACYLGLYCEROL BLOOD LEVEL;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; FEMALE; HEART FAILURE; HUMANS; MOLECULAR TARGETED THERAPY; PROTEIN KINASE INHIBITORS; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME; WOMEN'S HEALTH;

EID: 78649237682     PISSN: 15582027     EISSN: None     Source Type: Journal    
DOI: 10.2459/JCM.0b013e328336b4c1     Document Type: Review

References (61)

1. Brenner H. Long-term survival rates of cancer patients achieved by the end of the 20th century: a period analysis. Lancet 2002; 360:1131-1135. (Pubitemid 35246487)
2. Roger VL, Weston SA, Redfield MM, Hellermann-Homan JP, Killian J, Yawn BP, Jacobsen SJ. Trends in heart failure incidence and survival in a community-based population. JAMA 2004; 292:344-350.
3. Jones LW, Haykowsky MJ, Swartz JJ, Douglas PS, Mackey JR. Early breast cancer therapy and cardiovascular injury. J Am Coll Cardiol 2007; 50:1435-1441.
4. Grande E, Inghelmann R, Francisci S, Verdecchia A, Micheli A, Baili P, et al. Regional estimatesof breastcancer burden in Italy. Tumori 2007;93:374-379. (Pubitemid 47403453)
5. Lloyd-Jones DM, Leip EP, Larson MG, D'Agostino RB, Beiser A, Wilson PW, et al. Prediction of lifetime riskforcardiovasculardisease by riskfactor burden at 50 years of age. Circulation 2006; 113:791-798.
6. Irwin ML, Smith AW, McTiernan A, Ballard-Barbash R, Cronin K, Gilliland FD, et al. Influence ofpreand postdiagnosis physical activity on mortality in breastcancersurvivors:the health,eating,activity, and lifestylestudy.JClin Oncol 2008; 24:3958-3964.
7. Perez EA, Suman VJ, Davidson NE, Sledge GW, Kaufman PA, Hudis CA, et al. Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breastcancertrial.JClin Oncol 2008; 26:1231-1238.
8. Tan-Chiu E, Yothers G, Romond E, Geyer CE Jr, Ewer M, Keefe D, et al. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab asadjuvanttherapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J Clin Oncol 2005; 23:7811-7819.
9. Smith I, Procter M, Gelber RD, Guillaume S, Feyereislova A, Dowsett M, et al. 2-yearfollow-upoftrastuzumabafteradjuvantchemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 2007; 369:29-36.
10. Slamon D, Eiermann W, Robert N. BCIRG 006: 2nd interim analysis phase III randomized trial comparing doxorubicin and cyclophosphamide followed bydocetaxel (AC->T)with doxorubicin and cyclophosphamidefollowed by docetaxel and trastuzumab (AC->TH) with docetaxel, carboplatin and trastuzumab (TCH) in Her2neu positive early breast cancer patients [abstract]. In: Proceedings of the 29th Annual San Antonio Breast Cancer Symposium; 2006; San Antonio, Texas.
11. Yeh ETH, Bickford CL. Cardiovascular complications of cancer therapy. JAm Coll Cardiol 2009; 53:2231-2247.
12. Riccio G, Esposito G, Leoncini E, Contu R, Condorelli G, Chiariello M, et al. Cardiotoxic effects, or lack thereof anti-ErbB2 immunoagents. FASEB J 2009; 23:3171-3178.
13. Di Lorenzo G, Autorino R, Bruni G, Carteǹi G, Ricevuto E, Tudini M, et al. Cardiovascular toxicity following sunitinib therapy in metastatic renal cell carcinoma: a multicenter analysis. Ann Oncol 2009; 20:1535-1542.
14. Telli ML, Witteles RM, Fisher GA, Srinivas S. Cardiotoxicity associated with thecancertherapeuticagentsunitinib malate.Ann Oncol2008; 19:1613-1618.
15. Khakoo AY, Kassiotis CM, Tannir N, Plana JC, Halushka M, Bickford C, et al. Heartfailureassociatedwith sunitinib malate: amultitargeted receptor tyrosine kinase inhibitor. Cancer2008; 112:2500-2508.
16. Khakoo AY, Yeh ET. Therapy insight: management of cardiovascular disease in patients with cancer and cardiac complications of cancer therapy. Nat Clin Pract Oncol 2008; 5:655-667.
17. Yusuf SW, Razeghi P, Yeh ET. The diagnosis and management of cardiovascular disease in cancer patients. Curr Probl Cardiol 2008; 33:163-196; Review.
18. Guglin M, Cutro R, Mishkin JD. Trastuzumab-induced cardiomyopathy. J Card Fail 2008; 14:437-444.
19. Sengupta PP, Northfelt DW, Gentile F, Zamorano JL, Khandheria BK. Trastuzumab-induced cardiotoxicity: heartfailure at the crossroads. Mayo Clin Proc 2008; 83:197-203.
20. Popat S, Smith IE. Therapy insight: anthracyclines and trastuzumab-the optimal management of cardiotoxic side effects. Nat Clin Pract 2008; 5:324-325.
21. Perik PJ, De Korte MA, Van Veldhuisen DJ, Gietema JA, Sleijfer DT, De Vries GE. Cardiotoxicity associated with the use of trastuzumab in breast cancer patients. Anticancer Ther 2007; 7:1763-1771.
22. Perez EA. Cardiac toxicity of ErbB2-targeted therapies: what do we know? Clin Breast Cancer 2008; 8:114-120.
23. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344:783-792.
24. Seidman A, Hudis C, Pierri MK, Shak S, Paton V, Ashby M, et al. Cardiac dysfunction inthetrastuzumabclinicaltrialsexperience.JClin Oncol2002; 20:1215-1221.
25. Bianchi G, Albanell J, Eiermann W,Vitali G, Borquez D,Viganò L, et al. Pilot trial of trastuzumab starting with or after the doxorubicin component of a doxorubicin plus paclitaxel regimen for women with HER2-positive advanced breast cancer. Clin Cancer Res 2003; 9:5944-5951.
26. Gianni L. Neoadjuvant trastuzumab in locally advanced breast cancer (NOAH): antitumour and safety analysis (abstract). J Clin Oncol 2007; 25:10s.
27. Ewer MS, Vooletich MT, Durand JB, Woods ML, Davis JR, Valero V, et al. Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment. J Clin Oncol 2005; 23:7820-7826.
28. Guarneri V, Lenihan DJ, Valero V, Durand JB, Broglio K, Hess KR, et al. Long-term cardiac tolerability oftrastuzumab in metastatic breast cancer: the M.D. Anderson Cancer Center experience. J Clin Oncol 2006; 24:4107-4115.
29. Chien KR. Herceptin and the heart: a molecular modifier of cardiac failure. N Engl J Med 2006; 354:789-790.
30. Suter TM, Procter M, Van Veldhuisen DJ, Muscholl M, Bergh J, Carlomagno C, et al. Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial. J Clin Oncol 2007; 25:3859-3865.
31. Mackey JR, Clemons M, Côté MA, Delgado D, Dent S, Paterson A, et al. Cardiac management during adjuvant trastuzumab therapy: recommendations of the Canadian Trastuzumab Working Group. Curr Oncol2008; 15:24-35.
32. Telli ML, Hunt SA, Carlson RW, Guardino AE. Trastuzumab-related cardiotoxicity: calling into question the conception of reversibility. J Clin Oncol 2007; 25:3525-3533.
33. Mann DL. Mechanisms and models in heart failure: a combinational approach. Circulation 1999; 100:999-1008.
34. Sirohi B, Smith K. Bevacizumab in the treatment of breast cancer. Expert Rev Anticancer Ther 2008; 8:1559-1568.
35. Sica DA. Angiogenesis inhibitors and hypertension: an emerging issue. J Clin Oncol 2006; 24:1329-1331.
36. Miller KD, Chap LI, Holmes FA, Cobleigh MA, Marcom PK, Fehrenbacher L, et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 2005; 23:792-799.
37. Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007; 357:2666-2676.
38. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350:2335-2342.
39. Pande A, Lombardo J, Spangenthal E, Javle M. Hypertension secondary to antiangiogenic therapy: experience with bevacizumab. Anticancer Res 2007; 27:3465-3470.
40. Cobleigh MA, Langmuir VK, Sledge GW, Miller KD, Haney L, Novotny WF. A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer. Semin Oncol 2003; 30:117-124.
41. Johnson DH, Fehrenbacher L, Novotny WF, Herbst RS, Nemunaitis JJ, Jablons DM, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic nonsmall-cell lung cancer. J Clin Oncol 2004; 22:2184-2191.
42. Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ, Topalian SL, et al.A randomized trial of bevacizumab, an antivascularendothelial growth factorantibody,formetastatic renal cancer. N Engl J Med 2003;349:427-434.
43. Burstein HJ, Elias AD, Rugo HS, Cobleigh MA, Wolff AC, Eisenberg PD, et al. Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 2008; 26:1810-1816.
44. Motzer RJ, Michaelson MD, Redman BG, Hudes GR, Wilding G, Figlin RA, et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 2006; 24:16-24.
45. Demetri GD,van Oosterom AT, Garrett CR, Blackstein ME, Shah MH, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromaltumourafterfailureofimatinib: arandomised controlled trial. Lancet 2006; 368:1329-1338.
46. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007; 356:115-124.
47. Motzer RJ, Rini BI, Bukowski RM, Curti BD, George DJ, Hudes GR, et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 2006; 295:2516-2524.
48. Chu TF, Rupnick MA, Kerkela R, Dallabrida SM, Zurakowski D, Nguyen L, et al. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet 2007; 370:2011-2019.
49. Telli ML, Witteles RM, Fisher GA, Srinivas S. Cardiotoxicityassociated with thecancertherapeuticagentsunitinib malate.Ann Oncol2008; 19:1613-1618.
50. Kamba T, McDonald DM. Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br J Cancer 2007; 96:1788-1795.
51. Perez EA. Safety profiles of tamoxifen and the aromatase inhibitors in adjuvant therapy of hormone-responsive early breast cancer. Ann Oncol 2007; 18:26-35.
52. Breast International Group (BIG) 1-98 Collaborative Group, Thürlimann B, Keshaviah A, Coates AS, Mouridsen H, Mauriac L, Forbes JF, et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 2005; 353:2747-2757. (Pubitemid 43016814)
53. Lewis S. Do endocrine treatments for breast cancer have a negative impact on lipid profiles and cardiovascular risk in postmenopausal women? Am Heart J 2007; 153:182-188.
54. Wojtacki J, Lesniewski-Kmak K, Pawlak W. Anastrazole therapy and lipid profile: an update. Eur J Cancer 2004; 2 (Suppl 3):142.
55. Elisaf MS, Bairaktari ET, Nicolaides C, Kakaidi B, Tzallas CS, Katsaraki A, et al. Effect of letrozole on the lipid profile in postmenopausal women with breast cancer. Eur J Cancer 2001; 37:1510-1513.
56. Atalay G, Dirix L, Biganzoli L, Beex L, Nooij M, Cameron D, et al. The effect of exemestane on serum lipid profile in postmenopausal women with metastatic breast cancer: a companion study to EORTCTrial 10951, 'Randomized phase II study in first line hormonal treatment for metastatic breast cancer with exemestane or tamoxifen in postmenopausal patients'. Ann Oncol 2004; 15:211-217.
57. Fallah-Rad N, Lytwyn M, Fang T, Kirkpatrick I, Jassal DS. Delayed contrast enhancementcardiacmagnetic resonance imaging intrastuzumab induced cardiomyopathy. J Cardiovasc Magn Reson 2008; 10:5.
58. Perik PJ, de Vries EG, Gietema JA, van der Graaf WT, Smilde TD, Sleijfer DT, et al. Serum HER2 levels are increased in patients with chronic heart failure. Eur J Heart Fail 2007; 9:173-177.
59. Tassan-Mangina S, Codorean D, Metivier M, Costa B, Himberlin C, Jouannaud C, et al. Tissue Doppler imaging and conventional echocardiography after anthracycline treatment in adults: early and late alterations of left ventricular function during a prospective study. Eur J Echocardiogr 2006; 7:141-146.
60. Cardinale D, Sandri MT, Colombo A, Colombo N, Boeri M, Lamantia G, et al. Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy. Circulation 2004; 109:2749-2754.
61. Cardinale D, Colombo A, Sandri MT, Lamantia G, Colombo N, Civelli M, et al. Prevention ofhigh-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation 2006; 114:2474-2481.